A Study to Evaluate Intramuscular ASP7374

Phase 3

Completed

• Conditions: Vaccine; Influenza

• Registration Number: NCT01961960
• Lead Sponsor: UMN Pharma Inc.

Brief Summary

The purpose of this study is to evaluate safety and immunogenicity of intramuscular ASP7374 in adults ≥61 years of age.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-10
• Study First Submitted: 2013-10-10
• Study First Submitted QC: 2013-10-10
• Study First Posted: 2013-10-14
• Primary Completion: 2013-11
• Study Completion: 2013-11
• Status Verified: 2017-09
• Last Update Submitted: 2017-09-27
• Last Update Posted: 2017-09-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 55

Inclusion Criteria

• Healthy or medically stable, as judged on the basis of history and concurrent diseases.
• Subject understands procedure of the protocol and is willing to comply with the protocol.
• Written informed consent has been obtained.

Exclusion Criteria

• Scheduled to receive another vaccine during the study.
• Received influenza HA vaccine within 180 days prior to screening.
• Received or scheduled to receive a live vaccine within 28 days prior to vaccination with the study vaccine, and received or scheduled to receive an inactivated vaccine or a toxoid within 7 days prior to vaccination with the study vaccine.
• Diagnosis of immune deficit in the past, has a family member (within the third degree of kinship) with a diagnosis of congenital immunodeficiency syndrome.
• Received one of the following medications or treatment prior to vaccination with the study vaccine: Interferon formulation, Drugs which affect the immune system, corticosteroids, G-CSF, M-CSF, Human immunoglobulin products, Blood products, Blood transfusion
• History of anaphylactic shock or an allergic reaction such as generalized eruption due to food or drug (including vaccines) allergies, fever ≥39.0°C within 2 days after the previous vaccination (influenza vaccine and others)
• History of seizures, except for febrile seizures in childhood

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
hemagglutination inhibition (HI) antibody titer	Day 1 and Day 29	evaluated for A/H1N1, A/H3N2, and B

Secondary Outcome Measures

Name	Time	Method
neutralizing antibody titer	Day 1 and Day 29	evaluated for A/H1N1, A/H3N2, and B
Local and systemic reactions associated with the vaccination	Day 1 through Day 8